Longeveron Inc. (LGVN) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Longeveron Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.959 -- 00:00:06.164 Greetings and welcome to the Longeviron 2025 Q2 Financial Results 00:00:06.164 -- 00:00:12.070 and Business Update Call. At this time, all participants are in a listen-only mode. 00:00:12.070 -- 00:00:15.994 A brief question and answer session will follow the formal presentation. 00:00:15.994 -- 00:00:20.218 If anyone should require operator assistance during the conference, please press star, 00:00:20.218 -- 00:00:23.181 then zero, on your telephone keypad. 00:00:23.181 -- 00:00:26.445 As a reminder, this conference is being recorded. 00:00:26.445 -- 00:00:31.334 It is now my pleasure to introduce your host, Derek Cole, Investor Relations. 00:00:31.334 -- 00:00:34.097 Thank you. You may begin. 00:00:34.097 -- 00:00:37.621 Thank you, operator. Good afternoon, everyone, and thank you for joining us today to 00:00:37.621 -- 00:00:42.806 review Longeviron's 2025 second quarter financial results and business update. 00:00:42.806 -- 00:00:46.490 After the U.S. markets closed today, we issued a press release with financial results 00:00:46.490 -- 00:00:48.332 for Q2 2025, 00:00:48.332 -- 00:00:52.497 which can be found under the investor section of the Longeviron website. 00:00:52.497 -- 00:00:56.641 On the call today are Wael Hashad, chief executive officer, Dr. 00:00:56.641 -- 00:01:02.045 Joshua Hare, co-founder, chief science officer, and chairman of the board, Natalia Agafanova, 00:01:02.045 -- 00:01:06.911 Chief Medical Officer, Lisa Locklear, Chief Financial Officer, and Devin Blass, Chief 00:01:06.911 -- 00:01:11.637 Technology Officer. As a reminder, during this call, we will be making forward-looking 00:01:11.637 -- 00:01:15.362 statements. These statements are subject to certain risks and uncertainties that could 00:01:15.362 ...